Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats

Area of Science:

• Hepatology
• Endocrinology
• Molecular Biology

Background:

• Nonalcoholic fatty liver disease (NAFLD) is a prevalent condition with limited therapeutic options.
• There is a critical need for novel treatments targeting hepatic steatosis and steatohepatitis.

Purpose of the Study:

• To investigate the therapeutic potential of thyroid hormone triiodothyronine (T3) and a TRbeta-specific agonist (GC-1) in a rodent model of NAFLD.
• To determine if T3 and GC-1 can prevent or reverse diet-induced fatty liver and steatohepatitis.

Main Methods:

• Rats were fed a choline-methionine deficient (CMD) diet to induce fatty liver and mild hepatitis.
• Concurrent or subsequent administration of T3 or GC-1 was evaluated.
• Biochemical and molecular analyses assessed liver steatosis, inflammation, and related pathways.

Main Results:

• T3 administration completely prevented CMD-induced fatty liver by increasing fatty acid oxidation.
• T3 treatment reversed established fatty liver, reducing lipid peroxidation and inflammatory markers.
• GC-1 effectively prevented and reversed hepatic fat accumulation and ameliorated steatohepatitis without cardiac side effects.

Conclusions:

• Thyroid hormone receptor (TR) agonists, including T3 and GC-1, demonstrate significant potential in inhibiting or reversing hepatic steatosis.
• TR agonists represent a promising therapeutic avenue for managing nutritional models of fatty liver disease.